News Lilly buys into psychedelics with $3.8bn AtaiBeckley deal AtaiBeckley has been snapped up by Eli Lilly in a massive $3.8bn transaction that shows psychedelic drugs are now firmly in the pharma mainstream.
News Psychedelic merger to create AtaiBeckley completes A $390m merger of two pioneers of psychedelic medicines has completed to create AtaiBeckley, with a pipeline of candidates for mental illnesses.
News GSK showcases positive data with lung cancer drugs at WCLC New data at WCLC26 could push GSK's ROS1+ NSCLC drug Jideytro into the first-line setting, while B7-H3-targeted ADC ris-rez extends survival in SCLC.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.